Neuroprotection in Acute Ischemic Stroke

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

August 2, 2017

Primary Completion Date

August 13, 2019

Study Completion Date

August 13, 2019

Conditions
Stroke, Ischemic
Interventions
DRUG

Hydrogen

Hydrogen will be infused into bags of normal saline solution and administered intravenously, or hydrogen generating tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days.

DRUG

Minocycline

"Minocycline 200 mg will be mixed with normal saline and given by i.v. administration, or provided as capsules for the patient to swallow, q 24 hours for 5 days.~Once patients regain the ability to swallow capsules, minocycline will be given orally in capsule form (2 capsules of 100 mg each), administered once daily for the remainder of the 5 day period."

OTHER

Placebo Hydrogen

"Normal saline solution will be administered intravenously, in place of hydrogen solution.~Placebo tablets will be dissolved into water for the patient to drink, as the patient's condition permits. This will be administered TID for 3 days."

OTHER

Placebo Minocycline

Normal saline solution or placebo capsule will be administered i.v. or p.o. respectively, in place of minocycline.

Trial Locations (1)

11794-8121

Stony Brook University Hospital, Stony Brook

All Listed Sponsors
lead

Stony Brook University

OTHER

NCT03320018 - Neuroprotection in Acute Ischemic Stroke | Biotech Hunter | Biotech Hunter